A Cell study reported a new oral beta-2 agonist-based drug that lowers blood sugar and boosts fat burning by targeting skeletal muscle metabolis-without reducing appetite or muscle mass. Early trials show good tolerability, offering a potential alternative or complement to GLP-1 drugs. A phase II trial will further assess its benefits in diabetes and obesity.